GlassScriptPhysician profile
Sonya M Tran
NPI 1669544615
$3,410.23
in general payments reported to CMS, 2019-2025
38 companies · $535 in 2025
The $535 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $248 · 2021: $468 · 2022: $584 · 2023: $373 · 2024: $624 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.34 | 2019-2025 | Lo Loestrin Fe, Vraylar, Orilissa |
| Sumitomo Pharma America, INC. | $332.46 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $253.85 | 2020-2024 | Injectafer |
| Hologic Sales and Service, LLC | $219.23 | 2019-2025 | Aptima, Thinprep 2000 Processor, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Bayer Healthcare Pharmaceuticals INC. | $162.55 | 2019-2023 | |
| Organon LLC | $161.46 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $149.18 | 2021-2024 | |
| Glaxosmithkline, LLC. | $132.89 | 2019 | |
| Coopersurgical, INC. | $125.24 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Therapeuticsmd, INC. | $108.19 | 2019-2022 | |
| Astellas Pharma US INC | $100.54 | 2019-2025 | Veozah |
| Novo Nordisk INC | $97.07 | 2019-2025 | Wegovy |
| Exeltis, USA INC. | $75.45 | 2022-2025 | Slynd |
| Allergan, INC. | $64.67 | 2019-2020 | |
| Ethicon US, LLC | $57.26 | 2020-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $50.13 | 2025 | |
| Biogen, INC. | $49.86 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $42.47 | 2022-2023 | |
| Pacira Pharmaceuticals Incorporated | $38.76 | 2019-2024 | Exparel |
| Acella Pharmaceuticals, LLC | $38.65 | 2024-2025 | NP Thyroid 60 |
| Dysis Medical, INC. | $35.99 | 2021 | |
| Amgen INC. | $29.51 | 2022-2023 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $28.61 | 2021-2023 | Gardasil 9 |
| Medtronic, INC. | $26.39 | 2022-2024 | Truclear |
| Amag Pharmaceuticals, INC. | $26.06 | 2019 | |
| Duchesnay USA Incorporated | $25.57 | 2019 | |
| Boston Scientific Corporation | $24.38 | 2022 | |
| Smith+Nephew, INC. | $21.87 | 2025 | Pico |
| Genzyme Corporation | $19.42 | 2022 | |
| Vertical Pharmaceuticals, LLC | $18.28 | 2019 | |
| Seqirus USA INC | $16.54 | 2025 | Fluad, Flucelvax |
| Sanofi Pasteur INC. | $16.34 | 2024 | |
| Scynexis, INC. | $15.12 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.94 | 2021 | |
| Myovant Sciences INC. | $14.48 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.13 | 2022 | |
| Meditrina | $12.70 | 2021 | |
| Eisai INC. | $11.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.